Search Results - "Ong, Voon"

Refine Results
  1. 1

    Using Autoantibodies and Cutaneous Subset to Develop Outcome‐Based Disease Classification in Systemic Sclerosis by Nihtyanova, Svetlana I., Sari, Alper, Harvey, Jennifer C., Leslie, Anna, Derrett‐Smith, Emma C., Fonseca, Carmen, Ong, Voon H., Denton, Christopher P.

    Published in Arthritis & rheumatology (Hoboken, N.J.) (01-03-2020)
    “…Objective To describe the associations between autoantibodies, clinical presentation, and outcomes among patients with systemic sclerosis (SSc) in order to…”
    Get full text
    Journal Article
  2. 2

    Association of anti-RNA polymerase III autoantibodies and cancer in scleroderma by Moinzadeh, Pia, Fonseca, Carmen, Hellmich, Martin, Shah, Ami A, Chighizola, Cecilia, Denton, Christopher P, Ong, Voon H

    Published in Arthritis research & therapy (14-02-2014)
    “…We assessed the profile and frequency of malignancy subtypes in a large single-centre UK cohort for patients with scleroderma (systemic sclerosis; SSc). We…”
    Get full text
    Journal Article
  3. 3

    Renal Disease and Systemic Sclerosis: an Update on Scleroderma Renal Crisis by Cole, Alice, Ong, Voon H., Denton, Christopher P.

    Published in Clinical reviews in allergy & immunology (01-06-2023)
    “…Scleroderma renal crisis (SRC) is a life-threatening complication of systemic sclerosis (SSc) with a mortality of 20% at 6 months. Once the leading cause of…”
    Get full text
    Journal Article
  4. 4

    Prediction of Pulmonary Complications and Long‐Term Survival in Systemic Sclerosis by Nihtyanova, Svetlana I., Schreiber, Benjamin E., Ong, Voon H., Rosenberg, Daniel, Moinzadeh, Pia, Coghlan, J. Gerrard, Wells, Athol U., Denton, Christopher P.

    Published in Arthritis & rheumatology (Hoboken, N.J.) (01-06-2014)
    “…Objective To assess survival and incidence of organ‐based complications in a large single‐center cohort of unselected systemic sclerosis (SSc) patients, and to…”
    Get full text
    Journal Article
  5. 5

    Clinical and pathological significance of interleukin 6 overexpression in systemic sclerosis by Khan, Korsa, Xu, Shiwen, Nihtyanova, Svetlana, Derrett-Smith, Emma, Abraham, David, Denton, Christopher P, Ong, Voon H

    Published in Annals of the rheumatic diseases (01-07-2012)
    “…To determine the potential clinical and pathological significance of altered expression of interleukin 6 (IL-6) in systemic sclerosis (SSc). Serum IL-6 and…”
    Get more information
    Journal Article
  6. 6
  7. 7
  8. 8

    Dynamic Prediction of Pulmonary Hypertension in Systemic Sclerosis Using Landmark Analysis by Nihtyanova, Svetlana I., Schreiber, Benjamin E., Ong, Voon H., Wells, Athol U., Coghlan, John G., Denton, Christopher P.

    Published in Arthritis & rheumatology (Hoboken, N.J.) (01-03-2023)
    “…Objective Pulmonary hypertension (PH) is a serious complication of systemic sclerosis (SSc). In this study, we explored the prediction of short‐term risk for…”
    Get full text
    Journal Article
  9. 9

    The Use of Cyclosporine A in Rheumatology: a 2016 Comprehensive Review by Chighizola, Cecilia Beatrice, Ong, Voon H., Meroni, Pier Luigi

    Published in Clinical reviews in allergy & immunology (01-06-2017)
    “…Cyclosporine A, an inhibitor of calcineurin, exerts an immunomodulator action interfering with T cell activation. Even though novel therapeutic tools have…”
    Get full text
    Journal Article
  10. 10

    Consensus best practice pathway of the UK Scleroderma Study Group: digital vasculopathy in systemic sclerosis by Hughes, Michael, Ong, Voon H, Anderson, Marina E, Hall, Frances, Moinzadeh, Pia, Griffiths, Bridget, Baildam, Eileen, Denton, Christopher P, Herrick, Ariane L

    Published in Rheumatology (Oxford, England) (01-11-2015)
    “…Digital vasculopathy (comprising RP, digital ulceration and critical digital ischaemia) is responsible for much of the pain and disability experienced by…”
    Get full text
    Journal Article
  11. 11

    A Phenome-Wide Association Study of Drugs and Comorbidities Associated With Gastrointestinal Dysfunction in Systemic Sclerosis by Maclean, Rory H, Ahmed, Fiza, Ong, Voon H, Murray, Charles D, Denton, Christopher P

    Published in Journal of rheumatology (01-07-2023)
    “…To explore the causes of and contributors to gastrointestinal (GI) dysfunction in systemic sclerosis (SSc) in a phenome-wide association study (PheWAS), using…”
    Get full text
    Journal Article
  12. 12
  13. 13

    Combinations of scleroderma hallmark autoantibodies associate with distinct clinical phenotypes by Clark, Kristina E. N., Campochiaro, Corrado, Host, Lauren V., Sari, Alper, Harvey, Jennifer, Denton, Christopher P., Ong, Voon H.

    Published in Scientific reports (02-07-2022)
    “…Systemic sclerosis (SSc) is characterized by the presence of SSc-specific or SSc-associated antibodies (SSc-Abs): anti-topoisomerase I (ATA), anti-centromere…”
    Get full text
    Journal Article
  14. 14

    Sustained benefit from intravenous immunoglobulin therapy for gastrointestinal involvement in systemic sclerosis by Raja, Jasmin, Nihtyanova, Svetlana I, Murray, Charles D, Denton, Christopher P, Ong, Voon H

    Published in Rheumatology (Oxford, England) (01-01-2016)
    “…IVIG is known to confer significant benefit in rheumatologic conditions, including inflammatory myopathy. This study aimed to assess the efficacy of IVIG…”
    Get full text
    Journal Article
  15. 15
  16. 16

    Diffuse cutaneous systemic sclerosis following SARS-Co V-2 vaccination by Cole, Alice, Thomas, Rhys, Goldman, Nina, Howell, Kevin, Chakravarty, Kuntal, Denton, Christopher P., Ong, Voon H.

    Published in Journal of autoimmunity (01-04-2022)
    “…The largest world-wide vaccination rollout ever is currently underway to tackle the covid-19 pandemic. We report a case of diffuse cutaneous systemic sclerosis…”
    Get full text
    Journal Article
  17. 17

    Zibotentan in systemic sclerosis-associated chronic kidney disease: a phase II randomised placebo-controlled trial by Stern, Edward P, Host, Lauren V, Wanjiku, Ivy, Escott, K Jane, Gilmour, Peter S, Ochiel, Rachel, Unwin, Robert, Burns, Aine, Ong, Voon H, Cadiou, Helen, O'Keeffe, Aidan G, Denton, Christopher P

    Published in Arthritis research & therapy (01-06-2022)
    “…We report results from a phase II randomised placebo-controlled trial assessing zibotentan, a highly selective endothelin receptor antagonist (ERA), in chronic…”
    Get full text
    Journal Article
  18. 18
  19. 19

    Absence of Clinically Meaningful Drug-Drug Interactions with Rezafungin: Outcome of Investigations by Flanagan, Shawn, Walker, Helen, Ong, Voon, Sandison, Taylor

    Published in Microbiology spectrum (15-06-2023)
    “…Rezafungin is a novel once-weekly echinocandin for intravenous injection currently in development for the treatment of infections and the prevention of ,…”
    Get full text
    Journal Article
  20. 20

    The Yin and Yang of IL-17 in Systemic Sclerosis by Wei, Lanxuan, Abraham, David, Ong, Voon

    Published in Frontiers in immunology (04-05-2022)
    “…IL-17 (IL-17A) is a pro-inflammatory cytokine produced by a sub-set of T helper cells termed Th17 cells primarily in response to cytokines like TGF-β and IL-23…”
    Get full text
    Journal Article